文献速递肿瘤 PET/CT核素与放射性配体治疗

PSMA-PET/CT引导的挽救性放疗治疗前列腺癌淋巴结复发后的结局

Outcome after PSMA-PET/CT-based salvage radiotherapy for nodal recurrence after radical prostatectomy.
PubMed 文献 · Eur J Nucl Med Mol Imaging · 2021-10-10

该回顾性研究纳入100例根治性前列腺切除术后淋巴结复发患者,均接受基于PSMA-PET/CT的挽救性选择性淋巴结放疗。中位随访37个月,1年、2年、3年生化无复发生存率分别为80.7%、71.6%、65.8%,远处转移无生存率分别为91.6%、79.1%、66.4%。同步雄激素剥夺治疗、ADT持续时间≥12个月、盆腔淋巴结定位与改善BRFS相关,同步ADT和放疗前PSA<1 ng/ml与改善DMFS相关。

要点

  • PSMA-PET/CT引导的sENRT在淋巴结复发前列腺癌中显示较高的BRFS和DMFS。
  • 同步ADT、ADT≥12个月及盆腔淋巴结定位与改善BRFS相关。
  • 同步ADT和放疗前PSA<1 ng/ml与改善DMFS相关,淋巴结数量无显著关联。

核心结论

  • PSMA-PET/CT的高敏感性和特异性转化为基于该影像的sENRT后相对较高的BRFS和DMFS。
  • 同步ADT、ADT持续时间、sRT前PSA值和淋巴结转移定位是改善结局的显著因素。

研究设计与样本

  • 回顾性分析100例连续接受PSMA-PET/CT引导的挽救性选择性淋巴结放疗的淋巴结复发前列腺癌患者。
  • 患者因根治性前列腺切除术后生化持续(76%)或生化复发(24%)接受PSMA-PET/CT扫描。

主要发现

  • 中位随访37个月,生化持续患者PSMA-PET/CT时中位PSA为1.7 ng/ml(范围0.1-40.1),生化复发患者为1.4 ng/ml(范围0.3-5.1)。
  • PSMA-PET/CT检出1、2和3个及以上淋巴结转移的比例分别为35%、23%和42%。
  • 83%患者仅有盆腔淋巴结转移,2%仅有腹主动脉旁,15%同时有盆腔和腹主动脉旁淋巴结转移。
  • 1年、2年、3年BRFS分别为80.7%、71.6%、65.8%,DMFS分别为91.6%、79.1%、66.4%。

关键数值与推荐

  • 前列腺窝累积总剂量转换为EQD21.5 Gy为66 Gy(60-70 Gy)。
  • 局部复发(若存在)剂量为70 Gy(66-72 Gy),PET阳性淋巴结为65.1 Gy(56-66 Gy),淋巴引流路径为47.5 Gy(42.4-50.9 Gy)。
  • 83%患者接受同步雄激素剥夺治疗(ADT)。
  • 多因素分析中,同步ADT、较长ADT持续时间(≥12个月 vs <12个月)和淋巴结定位(盆腔 vs 腹主动脉旁)与改善BRFS相关。
  • 同步ADT和sRT前较低PSA值(<1 vs >1 ng/ml)与改善DMFS相关,受累淋巴结数量无此关联。

临床怎么用

  • 对于根治性前列腺切除术后淋巴结复发患者,可考虑基于PSMA-PET/CT的挽救性选择性淋巴结放疗。
  • 同步ADT及ADT持续时间≥12个月可能与改善生化控制相关。
  • 放疗前PSA<1 ng/ml可能与改善远处转移控制相关。
  • 盆腔淋巴结转移患者可能较腹主动脉旁转移患者有更好的生化结局。

局限性

  • 回顾性研究设计。
  • 样本量有限(100例)。
  • 中位随访时间37个月。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Nodal recurrent prostate cancer (PCa) represents a common state of disease, amenable to local therapy. PSMA-PET/CT detects PCa recurrence at low PSA levels. The aim of this study was to evaluate the outcome of PSMA-PET/CT-based salvage radiotherapy (sRT) for lymph node (LN) recurrence. METHODS: A total of 100 consecutive patients treated with PSMA-PET/CT-based salvage elective nodal radiotherapy (sENRT) for LN recurrence were retrospectively examined. Patients underwent PSMA-PET/CT scan due to biochemical persistence (bcP, 76%) or biochemical recurrence (bcR, 24%) after radical prostatectomy (RP). Biochemical recurrence-free survival (BRFS) defined as PSA < post-RT nadir + 0.2 ng/ml and distant metastasis-free survival (DMFS) were calculated using the Kaplan-Meier method and uni- and multivariate analysis was performed. RESULTS: Median follow-up was 37 months. Median PSA at PSMA-PET/CT was 1.7 ng/ml (range 0.1-40.1) in patients with bcP and 1.4 ng/ml (range 0.3-5.1) in patients with bcR. PSMA-PET/CT detected 1, 2, and 3 or more LN metastases in 35%, 23%, and 42%, respectively. Eighty-three percent had only pelvic, 2% had only paraaortic, and 15% had pelvic and paraaortic LN metastases. Cumulatively, a total dose converted to EQD21.5 Gy of 66 Gy (60-70 Gy) was delivered to the prostatic fossa, 70 Gy (66-72 Gy) to the local recurrence, if present, 65.1 Gy (56-66 Gy) to PET-positive lymph nodes, and 47.5 Gy (42.4-50.9 Gy) to the lymphatic pathways. Concomitant androgen deprivation therapy (ADT) was administered in 83% of patients. One-, 2-, and 3-year BRFS was 80.7%, 71.6%, and 65.8%, respectively. One-, 2-, and 3-year DMFS was 91.6%, 79.1%, and 66.4%, respectively. In multivariate analysis, concomitant ADT, longer ADT duration (≥ 12 vs. < 12 months) and LN localization (pelvic vs. paraaortic) were associated with improved BRFS and concomitant ADT and lower PSA value before sRT (< 1 vs. > 1 ng/ml) with improved DMFS, respectively. No such association was seen for the number of affected lymph nodes. CONCLUSIONS: Overall, the present analysis shows that the so far, unmatched sensitivity and specificity of PSMA-PET/CT translates in comparably high BRFS and DMFS after PSMA-PET/CT-based sENRT for patients with PCa LN recurrence. Concomitant ADT, duration of ADT, PSA value before sRT, and localization of LN metastases were significant factors for improved outcome.

来源:Eur J Nucl Med Mol Imaging,查看原文。版权归原作者所有。

引用

  1. Rogowski P, Trapp C, von Bestenbostel R, et al. Outcome after PSMA-PET/CT-based salvage radiotherapy for nodal recurrence after radical prostatectomy. Eur J Nucl Med Mol Imaging. 2021. PMID: 34628521. doi:10.1007/s00259-021-05557-z

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。